Jeremy Force, DO

Jeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.

Dr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.

Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.

Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.

Dr Jeremy Force illustrates how FES-PET aids in the care of patients with breast cancer through a clinical case.

A comprehensive analysis of the potential role of FES-PET imaging in assessing ER status in tumors that are difficult to biopsy and in evaluating the extent of disease.

Expert perspective on the applications of FES-PET imaging in treatment decision-making in patients with breast cancer.

Dr Gary Ulaner compares the role of FDG-PET and FES-PET imaging in ER+ Breast Cancer and the ability of each of the 2 techniques in assessing ER status.

Experts provide an overview of the imaging modalities that can detect estrogen receptor status in patients with breast cancer.

Gary Ulaner, MD, PhD and Jeremy Force, DO review estrogen receptor (ER)-positive breast cancer and the various strategies available for diagnosing estrogen receptor (ER)-positive breast cancer.